by Peter Ciszewski | Jan 3, 2019
Carol Satler, MD Vice President of Medical Affairs in North America for Sobi, discusses the ultra rare disease primary haemophagocytic lymphohistiocytosis (HLH) and a new FDA approved treatment Emapalumab. HLH is an often-fatal syndrome of hyperinflammation in...
by Peter Ciszewski | Jan 2, 2019
Ellen Ritchie, MD, Associate Professor of Clinical Medicine, Weill Cornell Medical College, an expert in the field of Myeloproliferative Neoplasms (MPNs), provides a brief understanding of what this rare blood cancer is and the role patients and their families play in...
by Peter Ciszewski | Jan 1, 2019
By Peter Ciszewski; December 23, 2018 Richard Thomas Maziarz, MD discusses the JULIET trial, a phase-2 study of tisagenlecleucel (marketed as KYMRIAH). In this study an international team of researchers evaluated 93 patients with relapsed or refractory diffuse...
by Peter Ciszewski | Dec 30, 2018
Dr. Jonathan Peled of Memorial Sloan Kettering Cancer Center discusses his study which looked at whether pre-HCT microbiota configuration may be an important determinant of post-transplantation outcomes. The study reported from a multicenter analysis conducted...
by Peter Ciszewski | Dec 29, 2018
Heather A. Lau, MD, Director, Lysosomal Storage Disease Program at NYU Langone in New York City discusses Mucopolysaccharidosis type I (MPS I). This condition was once divided into three separate syndromes: Hurler syndrome (MPS I-H), Hurler-Scheie syndrome (MPS...
